Vivos Therapeutics (VVOS) Net Cash Flow (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Net Cash Flow data on file, last reported at $91000.0 in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 102.32% year-over-year to $91000.0 in Q1 2026; TTM through Mar 2026 was -$11.7 million, a 4041.13% decrease from a year earlier, with the FY2025 full-year figure at -$4.2 million, down 191.82% from the prior year.
• Net Cash Flow for Q1 2026 stood at $91000.0, up from -$1.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for VVOS reached as high as $4.3 million in Q2 2024 and fell as low as -$9.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$2.0 million across 5 years, with a median of -$1.4 million in 2025.
• Across the five-year window, Net Cash Flow jumped 237.11% in 2024 and sank 1581.67% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$3.2 million in 2022, then jumped by 121.82% to $701000.0 in 2023, then tumbled by 108.56% to -$60000.0 in 2024, then sank by 1581.67% to -$1.0 million in 2025, then soared by 109.02% to $91000.0 in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $91000.0 in Q1 2026, -$1.0 million in Q4 2025, and -$1.4 million in Q3 2025.